The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis

被引:31
作者
Bartosik-Psujek, H [1 ]
Stelmasiak, Z [1 ]
机构
[1] Med Univ Lublin, Dept Neurol, PL-20090 Lublin, Poland
关键词
multiple sclerosis; tau protein; phosphotau protein;
D O I
10.1007/s00702-005-0327-z
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Total-tau protein is considered the marker of axon damage whereas the abnormally phosphorylated tau forms are mainly associated with Alzheimer's disease. An increase in total-tau levels was observed in neurodegenerative diseases, including multiple sclerosis (MS). In order to find out whether the phosphorylated tau forms occur in MS patients and to evaluate their clinical significance, the levels of total-tau (t-tau) and tau phosphorylated at Thr 181 (p-tau) were determined in 60MS patients (40 during relapse including 18 with the first relapse and 20 stable) and in 18 age-matched controls. The determinations were conducted in the cerebrospinal fluid (CSF) using the ELISA method. The levels of t-tau and p-tau were higher in MS patients than in controls; however, increased levels were not related to the clinical activity of the disease. In CSF of the patients with the first relapse the level of t-tau was significantly increased whilst the level of p-tau was not elevated.
引用
收藏
页码:339 / 345
页数:7
相关论文
共 25 条
[1]   Hepatitis B virus genotypes: comparison of genotyping methods [J].
Bartholomeusz, A ;
Schaefer, S .
REVIEWS IN MEDICAL VIROLOGY, 2004, 14 (01) :3-16
[2]   tau protein in cerebrospinal fluid - A biochemical marker for axonal degeneration in Alzheimer disease? [J].
Blennow, K ;
Wallin, A ;
Agren, H ;
Spenger, C ;
Siegfried, J ;
Vanmechelen, E .
MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1995, 26 (03) :231-245
[3]   Cerebrospinal fluid tau levels increase with age in healthy individuals [J].
Blomberg, M ;
Jensen, M ;
Basun, H ;
Lannfelt, L ;
Wahlund, LO .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2001, 12 (02) :127-132
[4]   Tau alteration and neuronal degeneration in tauopathies: mechanisms and models [J].
Brandt, R ;
Hundelt, M ;
Shahani, N .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2005, 1739 (2-3) :331-354
[5]   Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 [J].
Buerger, K ;
Zinkowski, R ;
Teipel, SJ ;
Tapiola, T ;
Arai, H ;
Blennow, K ;
Andreasen, N ;
Hofmann-Kiefer, K ;
DeBernardis, J ;
Kerkman, D ;
McCulloch, C ;
Kohnken, R ;
Padberg, F ;
Pirttilä, T ;
Schapiro, MB ;
Rapoport, SI ;
Möller, HJ ;
Davies, P ;
Hampel, H .
ARCHIVES OF NEUROLOGY, 2002, 59 (08) :1267-1272
[6]   The 14-3-3 protein in multiple sclerosis: a marker of disease severity [J].
Colucci, M ;
Roccatagliata, L ;
Capello, E ;
Narciso, E ;
Latronico, N ;
Tabaton, M ;
Mancardi, Gl .
MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (05) :477-481
[7]  
Fath T, 2002, J NEUROSCI, V22, P9733
[8]   TAU-PROTEIN AND THE NEUROFIBRILLARY PATHOLOGY OF ALZHEIMERS-DISEASE [J].
GOEDERT, M .
TRENDS IN NEUROSCIENCES, 1993, 16 (11) :460-465
[9]   Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF [J].
Hulstaert, F ;
Blennow, K ;
Ivanoiu, A ;
Schoonderwaldt, HC ;
Riemenschneider, M ;
De Deyn, PP ;
Bancher, C ;
Cras, P ;
Wiltfang, J ;
Mehta, PD ;
Iqbal, K ;
Pottel, H ;
Vanmechelen, E ;
Vanderstichele, H .
NEUROLOGY, 1999, 52 (08) :1555-1562
[10]   Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis [J].
Jiménez-Jiménez, FJ ;
Zurdo, JM ;
Hernanz, A ;
Medina-Acebrón, S ;
de Bostus, F ;
Barcenilla, B ;
Sayed, Y ;
Ayuso-Peralta, L .
ACTA NEUROLOGICA SCANDINAVICA, 2002, 106 (06) :351-354